About Sialidase-4
Sialidase-4 (NEU4) is a protein
from Homo sapiens identified by UniProt accession
Q8WWR8, 484 residues long.
MolForge cross-references it against 0 known binders and
45 disease associations.
Target properties
| Protein name | Sialidase-4 |
| UniProt accession | Q8WWR8 |
| Gene | NEU4 |
| Organism | Homo sapiens |
| Length | 484 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (1)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (45)
Diseases linked to this target (Open Targets).
- ulcerative colitis · score 0.22
- cancer antigen 125 measurement · score 0.10
- Crohn's disease · score 0.10
- sclerosing cholangitis · score 0.08
- psoriasis · score 0.08
- ankylosing spondylitis · score 0.08
- allergic asthma · score 0.07
- Barrett's esophagus · score 0.04
- hypertriglyceridemia 2 · score 0.04
- thyroid hormone metabolism, abnormal, 2 · score 0.03
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q8WWR8-F1 | alphafold | PREDICTED | 82.87 | — |
Amino-acid sequence (484 residues)
MGVPRTPSRT VLFERERTGL TYRVPSLLPV PPGPTLLAFV EQRLSPDDSH AHRLVLRRGT LAGGSVRWGA LHVLGTAALA EHRSMNPCPV HDAGTGTVFL FFIAVLGHTP EAVQIATGRN AARLCCVASR DAGLSWGSAR DLTEEAIGGA VQDWATFAVG PGHGVQLPSG RLLVPAYTYR VDRRECFGKI CRTSPHSFAF YSDDHGRTWR CGGLVPNLRS GECQLAAVDG GQAGSFLYCN ARSPLGSRVQ ALSTDEGTSF LPAERVASLP ETAWGCQGSI VGFPAPAPNR PRDDSWSVGP GSPLQPPLLG PGVHEPPEEA AVDPRGGQVP GGPFSRLQPR GDGPRQPGPR PGVSGDVGSW TLALPMPFAA PPQSPTWLLY SHPVGRRARL HMGIRLSQSP LDPRSWTEPW VIYEGPSGYS DLASIGPAPE GGLVFACLYE SGARTSYDEI SFCTFSLREV LENVPASPKP PNLGDKPRGC CWPS
Explore Sialidase-4 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets